Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 7/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6094463 | 0.92 | PDE4B (0.40) | PDE4BGPR119SLC6A4HRH3NSD2 | |
| SCHEMBL4414313 | 0.90 | PDE4B (0.39) | PDE4BGPR119SLC6A4HRH3NSD2 | |
| SCHEMBL6740792 | 0.89 | SLC6A4 (0.41) | SLC6A4HRH3MAPT | |
| SCHEMBL6995417 | 0.87 | SLC6A4 (0.39) | SLC6A4HRH3MAPT | |
| SCHEMBL6992027 | 0.86 | HRH3 (0.39) | PDE4BSLC6A4HRH3MAPT | |
| SCHEMBL5965689 | 0.86 | SLC6A4 (0.39) | GPR119SLC6A4HRH3NSD2EHMT2 | |
| SCHEMBL5965803 | 0.86 | GPR119 (0.41) | PDE4BGPR119SLC6A4HRH3NSD2 | |
| SCHEMBL5965715 | 0.86 | GPR119 (0.41) | PDE4BGPR119SLC6A4HRH3NSD2 | |
| SCHEMBL6739004 | 0.86 | POLB (0.40) | SLC6A4HRH3MAPT | |
| SCHEMBL6990939 | 0.85 | HRH3 (0.42) | SLC6A4HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229900-A1 | Bispidine compounds useful in the treatment of cardiac arrythmias | ADRA1B, ADRB2, ADRA1D | PDE4B 702/4885GPR119 1522/4885SLC6A4 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.